SAN CARLOS, Calif., Oct. 23, 2022 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation firm engineering high-fidelity vaccines to defend humankind from the results of bacterial ailments, at the moment introduced it’ll maintain a webcast and convention name tomorrow, October 24, 2022, at 8:00 a.m. Eastern Time to present topline outcomes from its Phase 1/2 proof-of-concept research evaluating the protection, tolerability and immunogenicity of VAX-24, the Company’s investigational 24-valent pneumococcal conjugate vaccine (PCV), in wholesome adults aged 18-64.
Those who would love to take part might entry the reside webcast right here, or register upfront for the teleconference right here. A reside webcast of the convention name can even be out there on the investor relations web page of the Vaxcyte company web site at www.vaxcyte.com. After the reside webcast, the occasion will stay archived on the Vaxcyte web site for 30 days.
About Vaxcyte
Vaxcyte is a vaccine innovation firm engineering high-fidelity vaccines to defend humankind from the results of bacterial ailments. The Company is creating broad-spectrum conjugate and novel protein vaccines to stop or deal with bacterial infectious ailments. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal illness. Vaxcyte is re-engineering the way in which extremely advanced vaccines are made via fashionable artificial methods, together with superior chemistry and the XpressCF™ cell-free protein synthesis platform, completely licensed from Sutro Biopharma, Inc. Unlike typical cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is meant to speed up its potential to effectively create and ship high-fidelity vaccines with enhanced immunological advantages. Vaxcyte’s pipeline additionally consists of VAX-XP, a PCV with an expanded breadth of protection of better than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to stop Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to gradual or cease the development of periodontal illness. Vaxcyte is pushed to eradicate or deal with invasive bacterial infections, which have severe and expensive well being penalties when left unchecked. For extra info, go to www.vaxcyte.com.
Forward-Looking Statements
This press launch accommodates forward-looking statements throughout the that means of The Private Securities Litigation Reform Act of 1995. These statements embrace, however aren’t restricted to, statements associated to the potential advantages of Vaxcyte’s vaccine candidates and Vaxcyte’s potential to effectively create and ship such high-fidelity vaccines; and different statements that aren’t historic truth. The phrases “believe,” “could,” “expect,” “may,” “potential,” “should,” “would” and comparable expressions (in addition to different phrases or expressions referencing future occasions, situations or circumstances) convey uncertainty of future occasions or outcomes and are meant to determine forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. These forward-looking statements are primarily based on Vaxcyte’s present expectations and precise outcomes and timing of occasions may differ materially from these anticipated in such forward-looking statements on account of dangers and uncertainties, together with, with out limitation, dangers associated to Vaxcyte’s product growth packages, together with growth timelines, success and timing of chemistry, manufacturing and controls and associated manufacturing actions, potential delays or incapability to acquire and keep required regulatory approvals for its vaccine candidates, and the dangers and uncertainties inherent with preclinical and scientific growth processes; the success, value and timing of all growth actions and scientific trials; impacts of COVID-19; and sufficiency of money and different funding to help Vaxcyte’s growth packages and different working bills. These and different dangers are described extra absolutely in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), together with, with out limitation, its Quarterly Report on Form 10-Q filed with the SEC on August 8, 2022 or in different paperwork Vaxcyte subsequently recordsdata with or furnishes to the SEC. All forward-looking statements contained on this press launch communicate solely as of the date on which they had been made and are primarily based on administration’s assumptions and estimates as of such date, and readers shouldn’t depend on the knowledge on this press launch as present or correct after its publication date. Vaxcyte undertakes no responsibility or obligation to replace any forward-looking statements contained on this launch on account of new info, future occasions or adjustments in its expectations, besides as required by relevant legislation.
Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
[email protected]
Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
[email protected]
